NASDAQ · NTRA
Natera, Inc.
$436.00+$11.58 (+2.73%)
Natera, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.32% below the high.
Loading market information…
NASDAQ · BLLN · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
BillionToOne, Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.66% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
BillionToOne, Inc.’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of $0.15. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow BillionToOne, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:16 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $128.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$436.00+$11.58 (+2.73%)
Natera, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.32% below the high.
$185.31+$2.72 (+1.49%)
Guardant Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.0% below the high.
$158.92+$1.04 (+0.66%)
GRAIL Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.54% below the high.
$52.17+$1.86 (+3.7%)
Veracyte, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.35% below the high.
$17.93-$0.06 (-0.33%)
NeoGenomics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.02% below the high.
$71.02+$6.33 (+9.79%)
GeneDx Holdings Corp.’s quoted price sits in the lower half of its reported 52-week range, 58.44% below the high.
$6.67+$0.04 (+0.6%)
Myriad Genetics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 20.41% below the high.
$21.68+$0.16 (+0.74%)
Fulgent Genetics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 30.15% below the high.
